Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock

TY - JOUR

T1 - Cardiac safety research consortium “shock II” think tank report

T2 - Advancing practical approaches to generating evidence for the treatment of cardiogenic shock

AU - Samsky, Marc D.

AU - Krucoff, Mitchell W.

AU - Morrow, David A.

AU - Abraham, William T.

AU - Aguel, Fernando

AU - Althouse, Andrew D.

AU - Chen, Eric

AU - Cigarroa, Joaquin E.

AU - DeVore, Adam D.

AU - Farb, Andrew

AU - Gilchrist, Ian C.

AU - Henry, Timothy D.

AU - Hochman, Judith S.

AU - Kapur, Navin K.

AU - Morrow, Valarie

AU - Ohman, E. Magnus

AU - O'Neill, William W.

AU - Piña, Ileana L.

AU - Proudfoot, Alastair G.

AU - Sapirstein, John S.

AU - Seltzer, Jonathan H.

AU - Senatore, Fred

AU - Shinnar, Meir

AU - Simonton, Charles A.

AU - Tehrani, Behnam N.

AU - Thiele, Holger

AU - Truesdell, Alexander G.

AU - Waksman, Ron

AU - Rao, Sunil V.

N1 - Funding Information: Adam DeVore reports research funding through his institution from the American Heart Association; Amgen; AstraZeneca; Bayer; Intra-Cellular Therapies; American Regent, Inc; the NHLBI; Novartis; and PCORI. He also provides consulting services for Amgen, AstraZeneca, Bayer, CareDx, InnaMed, LivaNova, Mardil Medical, Novartis, Procyrion, scPharmaceuticals, Story Health and Zoll and has also received non-financial support from Abbott for educational activities. Funding Information: David A. Morrow reports no conflicts relevant to this work and reports grants from Anthos Therapeutics, grants and personal fees from AstraZeneca, personal fees from Bayer Pharma, grants from Daiichi Sankyo, grants from Eisai,grants from GlaxoSmithKline, personal fees from InCarda, grants from Medicines Company, grants and personal fees from Merck & Co, grants and personal fees from Novartis, grants from Pfizer, grants from Quark, grants from Regeneron, grants and personal fees from Roche Diagnostics, grants from Siemens, grants from Takeda, and grants from Zora Biosciences outside the submitted work; Dr. Morrow is also a member of the TIMI Study Group which has received institutional research grant support through Brigham and Women's Hospital from Abbott; Amgen; Aralez; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BRAHMS, Daiichi-Sankyo; Eisai; GlaxoSmithKline; Intarcia; Janssen; MedImmune; Merck; Novartis; Pfizer; Poxel; Quark Pharmaceuticals; Regeneron; Roche; Siemens; Takeda; The Medicines Company; and Zora Biosciences. Funding Information: Navin K. Kapur is a consultant/receives speaker honoraria from Abbott, Abiomed, Boston Scientific, Medtronic, LivaNova, Getinge, MD Start, and Precardia as well as institutional research grants from Abiomed, Boston Scientific, and MD Start. Funding Information: Judith S. Hochman reports no conflicts relevant to this work; Dr. Hochman is PI for the ISCHEMIA trial for which, in addition to support by National Heart, Lung, and Blood Institute grant, there were in-kind donations for participating sites from Abbott Vascular; Medtronic, Inc.; St. Jude Medical, Inc.; Volcano Corporation; Arbor Pharmaceuticals, LLC; AstraZeneca Pharmaceuticals, LP; Merck Sharp & Dohme Corp.; Omron Healthcare, Inc.; and Amgen Inc.; and financial donations from Arbor Pharmaceuticals LLC and AstraZeneca Pharmaceuticals LP. Funding Information: As a result of these repeatedly demonstrated positive associations, regionalized systems of care have been implemented for time-critical scenarios. Transportation to level 1 trauma centers has reduced trauma-associated mortality by 15–20%. 13 Increased use of fibrinolytic therapy and improved survival has been associated with integrated and regionalized systems of care for patients with acute ischemic stroke. 14 , 15 Finally, coordination of ST elevation myocardial infarction (STEMI) care has served as the exemplar of operationalized systems of care. Emergency medical services, community hospitals, and tertiary referral centers seamlessly interact to form standardized “hub-and-spoke” STEMI networks to ensure timely reperfusion. Supported by the American Heart Association (AHA) and its Mission: Lifeline program, this system further provides quality assurance via real-time feedback and mechanisms for quality improvement via educational programs. 8 , 16-21

PY - 2020/12

Y1 - 2020/12

UR - https://www.scopus.com/pages/publications/85093939285

UR - https://www.scopus.com/pages/publications/85093939285#tab=citedBy

U2 - 10.1016/j.ahj.2020.09.015

DO - 10.1016/j.ahj.2020.09.015

M3 - Article

C2 - 33011148

AN - SCOPUS:85093939285

SN - 0002-8703

VL - 230

SP - 93

EP - 97

JO - American Heart Journal

JF - American Heart Journal

ER -